Paysign Inc. Earnings Call Highlights Rapid Profit Surge

PaySign Inc Class B ((PAYS)) has held its Q4 earnings call. Read on for the main highlights of the call.

Paysign Inc. Class B’s latest earnings call struck an optimistic tone, underscoring powerful top-line growth, sharp margin expansion, and accelerating traction in its patient affordability platform. Management acknowledged pockets of pressure in the plasma segment, regulatory and tax noise, and lingering investor skepticism, but positioned the business as entering 2026 with clear operating leverage and strong financial momentum.

Surging Revenue Underscores Business Momentum

Paysign delivered total revenue of $82.0 million for fiscal 2025, a 40.5% increase year over year, highlighting strong demand across both pharma and plasma offerings. The performance reflects rapid scaling of newer growth engines while the legacy plasma business continues to expand in absolute dollars despite mixed center-level trends.

Profitability Nearly Doubles as Margins Expand

Net income jumped 98% to $7.6 million and adjusted EBITDA climbed 107% to $19.9 million, showcasing significant earnings power emerging from the model. Operating margin expanded to 9.0% from 1.7% a year ago, a 723-basis-point improvement that signals meaningful cost discipline and better economics as volumes scale.

Patient Affordability Platform Becomes Growth Engine

The patient affordability business was the standout performer, with annual revenue soaring 167.8% to $33.9 million from $12.7 million in 2024. Processed claims increased about 79%, and the platform facilitated nearly $1.0 billion in financial assistance to more than 840,000 patients in 2025, reinforcing its strategic importance and high-margin profile.

Dynamic Rules Generate Significant Savings for Pharma Clients

Management highlighted the impact of dynamic business rules, a key differentiator for pharmaceutical partners using Paysign’s programs. These capabilities saved clients over $325 million in 2025 and have already delivered almost $150 million in savings year-to-date, underscoring a compelling return on investment and helping support deeper client relationships.

Program Expansion Deepens Pharmaceutical Relationships

The company added 55 patient affordability programs in 2025, bringing the total to 131 active programs across more than 70 clients. Critically, Paysign now supports programs for 6 of the top 10 U.S. pharmaceutical manufacturers by revenue, signaling growing acceptance among large-cap pharma and a broader runway for future program launches.

Plasma Segment Grows but Faces Center-Level Pressure

Paysign’s plasma business generated $45.6 million in revenue for 2025, up 4% year over year, and exited the year with 595 centers, an increase of 115 centers and roughly 50% market share. However, average monthly revenue per center declined, as elevated plasma inventory and fewer donations per center weighed on per-site economics despite network growth.

Margins Benefit From Operating Leverage

Gross margin improved to 59.4% from 55.1%, reflecting the mix shift toward higher-margin pharma programs and efficiency gains. Operating expenses rose 32.6%, well below the pace of revenue growth, reinforcing management’s view that the business has hit a fixed-cost inflection point where additional scale should increasingly fall to the bottom line.

Balance Sheet Strengthens With Cash Build and No Debt

The company ended the year with $21.1 million in cash, nearly double the prior year’s level, providing extra flexibility for investment and potential volatility in end markets. Importantly, Paysign carries zero bank debt, giving it a clean capital structure and reducing financial risk as it executes its growth strategy.

Margin Outlook Improves for Early 2026

For the first quarter of 2026, Paysign expects operating margin between 20% and 22% and net margin of 17% to 19%, indicating further near-term profitability gains. Adjusted EBITDA margin is projected in the 34.5% to 36.5% range, even as the company invests in growth, reflecting the high inherent operating leverage in the model.

Center Losses and Tax Rate Weigh on Near-Term Metrics

Management noted that six plasma centers—five sold to a competitor and one closed—will leave the network, with Q1 2026 now expected to end at 589 centers. Additionally, fourth quarter net income was pressured by a 45.4% effective tax rate, which reduced quarterly earnings per share by about $0.02 and masked some of the underlying operational strength.

Regulatory and FDA Uncertainties Remain Watchpoints

Executives flagged ongoing state-level developments around co-pay accumulator and maximizer programs as an area requiring vigilance, though they do not view current activity as a material threat. Separately, the company’s donor management BECS system remains under FDA 510(k) review, with the timing and ultimate outcome still uncertain, adding a layer of regulatory overhang.

Higher 2026 Operating Costs Temper, But Don’t Derail, Margins

Operating expenses are expected to rise about 20% in 2026 as Paysign ramps investment and absorbs growing non-cash charges. Depreciation and amortization are projected at $9.5 million to $10 million, while stock-based compensation should total roughly $5.5 million, partially offsetting margin gains but supporting long-term platform development.

Investor Perception Lags Improving Fundamentals

Management called out a disconnect between the company’s improving fundamentals and its stock market performance, suggesting the co-pay and patient affordability space remains poorly understood by many investors. They see education around the business model and the durability of the pharma opportunity as important steps toward narrowing this valuation gap over time.

Guidance Points to Another Year of Strong Growth

Paysign’s 2026 guidance calls for revenue of $106.5 million to $110.5 million, implying 30% to 35% year-over-year growth, with plasma and pharma contributing roughly equally and other revenue around $2.5 million. The company expects gross margins of 60% to 62%, net income of $13 million to $16 million, and adjusted EBITDA between $30 million and $33 million, alongside strong Q1 revenue and margin forecasts that factor in typical plasma and pharma seasonality.

The overall message from Paysign’s earnings call was that a high-growth, high-margin patient affordability franchise is now reshaping the company’s financial profile, while the plasma segment continues to provide scale. Despite some headwinds from center churn, regulatory watchpoints, and investor misunderstandings, the guidance and margin trajectory suggest a business entering 2026 with strengthening fundamentals and substantial operating leverage.